Company Profile
Proteomics International Laboratories is a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia.
It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis.
Its portfolio also includes PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis, and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy.
Its portfolio also includes Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease, Plant Dieback, that is under development phase for phytophthora dieback, Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy, and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy
Analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Founded in 2001, Proteomics International Laboratories is based in Perth, Australia.